1
|
Mongkonchoo K, Yamana H, Aso S, Machida M, Takasaki Y, Jo T, Yasunaga H, Chongsuvivatwong V, Liabsuetrakul T. Prediction of outpatient visits and expenditure under the Universal Coverage Scheme in Bangkok using subscriber's attributes: A random forest analysis. Public Health in Practice 2021; 2:100190. [PMID: 36101615 PMCID: PMC9461546 DOI: 10.1016/j.puhip.2021.100190] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2021] [Accepted: 09/22/2021] [Indexed: 10/26/2022] Open
|
2
|
Yoshida R, Yamana H, Hayashi M, Yasuda E, Shibayama Y, Hirose Y, Tanigawa N, Uchiyama K, Kubota T. Transplantation of Graft Anti-Host Cytotoxic T Lymphocytes Along with Allogeneic Bone Marrow Skips Macrophage-Induced Graft-Versus-Host Disease. J Interferon Cytokine Res 2021; 41:310-318. [PMID: 34543129 DOI: 10.1089/jir.2021.0032] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Graft-versus-host disease (GVHD) is a physiological response of the graft to allogeneic hosts. However, the effector cells, affected organ(s), and cytokines in the GVHD remain controversially discussed, without having determined a particular cytotoxic activity of the graft against the host. After i.v. injection of C57BL/6 (H-2b) spleen cells into irradiated BDF1 (H-2b/d) mice, the hosts developed interferon-gamma (IFN-γ)-dependent bone marrow (BM) GVHD on days 5-17. When H-2DdKd transgenic H-2b lymphoma cells were i.p. inoculated into irradiated, H-2b splenocyte-transplanted H-2b/d mice, the infiltration of macrophages cytotoxic against H-2DdKd transgenic H-2b mouse skin epithelia (a GVHD activity) into the peritoneal cavity preceded several days the infiltration of interleukin (IL)-2-dependent cytotoxic T lymphocytes (CTLs) to achieve a graft-versus-leukemia (GVL) effect. In contrast, allogeneic BM transplanted alone into the irradiated mice did not induce GVHD for 44 days, whereas i.v. injection of graft anti-host macrophages or graft anti-host CTLs along with allogeneic BM, respectively, induced GVHD or promoted the GVL effect in the absence of GVHD. These results revealed that macrophage-induced GVHD and the CTL-mediated GVL effect were a set (Th1: IFN-γ/IL-2) response of the graft to allogeneic hosts and leukemia cells, respectively, and that graft T cell activation rather than inhibition skipped GVHD after BM transplantation.
Collapse
Affiliation(s)
- Ryotaro Yoshida
- Department of Physiology, Osaka Medical and Pharmaceutical University, Takatsuki, Japan.,Research Laboratory, Osaka Medical and Pharmaceutical University, Takatsuki, Japan
| | - Hidenori Yamana
- Department of Physiology, Osaka Medical and Pharmaceutical University, Takatsuki, Japan.,Department of General and Gastroenterological Surgery, Osaka Medical College, Takatsuki, Japan
| | - Michihiro Hayashi
- Department of General and Gastroenterological Surgery, Osaka Medical College, Takatsuki, Japan
| | - Emi Yasuda
- Department of Pathology, Osaka Medical College, Takatsuki, Japan
| | - Yuro Shibayama
- Department of Pathology, Osaka Medical College, Takatsuki, Japan
| | - Yoshinobu Hirose
- Department of Pathology, Osaka Medical College, Takatsuki, Japan
| | - Nobuhiko Tanigawa
- Department of General and Gastroenterological Surgery, Osaka Medical College, Takatsuki, Japan
| | - Kazuhisa Uchiyama
- Department of General and Gastroenterological Surgery, Osaka Medical College, Takatsuki, Japan
| | - Takahiro Kubota
- Department of Physiology, Osaka Medical and Pharmaceutical University, Takatsuki, Japan
| |
Collapse
|
3
|
Honda C, Yamana H, Matsui H, Nagata S, Yasunaga H, Naruse T. Age in months and birth order in infant nonfatal injuries: A retrospective cohort study. Public Health in Practice 2020; 1:100005. [PMID: 36101695 PMCID: PMC9461530 DOI: 10.1016/j.puhip.2020.100005] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2020] [Accepted: 04/02/2020] [Indexed: 11/17/2022] Open
Abstract
Objective To examine the age in months at which infants visited outpatient clinics or emergency rooms for the first time for nonfatal injuries and to identify risk factors for the occurrence of these injuries. Study design Retrospective cohort study. Methods We used a health insurance claims database in Japan. Infants born between April 2012 and December 2014 were identified and followed until 12 months of age. We identified their first visit to outpatient clinics or emergency rooms because of nonfatal injuries (wounds/fractures, foreign bodies, and burns). Cox regression analysis was used to examine the association of nonfatal injuries with infants’ sex, birth order, and parental age. Results We identified 46,431 eligible infants. Of these, 7606 (16.4%) were brought to an outpatient clinic or emergency room for nonfatal injuries within 12 months of birth. Of the 7,606, 21.7% were aged ≤4 months and 44.7% ≤ 7 months. First-born infants were more likely to have wounds/fractures and burns. Conclusion One-fifth of first nonfatal infant injuries occurred within 4 months of age. Healthcare providers should provide early education about injury prevention, especially to caregivers of first-born infants. Nonfatal injuries within first year of birth occurred in 16% of infants. 22% of first injuries occurred within 4 months of birth. First-born infants were more likely to have wounds/fractures and burns.
Collapse
Affiliation(s)
- C. Honda
- Department of Community Health Nursing, Division of Health Sciences and Nursing, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
- Corresponding author. Department of Community Health Nursing, Division of Health Sciences and Nursing, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-0033, Japan.
| | - H. Yamana
- Department of Health Services Research, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
| | - H. Matsui
- Department of Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo, Tokyo, Japan
| | - S. Nagata
- Faculty of Nursing and Medical Care, Graduate School of Health Management, Keio University, Kanagawa, Japan
| | - H. Yasunaga
- Department of Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo, Tokyo, Japan
| | - T. Naruse
- Department of Community Health Nursing, Division of Health Sciences and Nursing, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
| |
Collapse
|
4
|
Tsuboshima K, Wakahara T, Matoba Y, Yamana H, Oue H, Watanabe Y, Ono T. [Injection of High Concentration Glucose Solution for Pleural Coating Reduces Postoperative Recurrence of Spontaneous Pneumothorax;A Short-term Retrospective Study]. Kyobu Geka 2017; 70:980-984. [PMID: 29104195] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/07/2023]
Abstract
BACKGROUND Video-assisted thoracoscopic surgery (VATS) is the standard treatment for patients with spontaneous pneumothorax (SP). However, postoperative recurrence is not infrequent even with an absorbable covering sheet used to reinforce the visceral pleura. Recent reports suggest that intraoperative injection of a highly concentrated glucose solution into the thoracic cavity provides effective prophylaxis against postoperative SP recurrence. Since September 2015, we have been injecting 50 ml of 50 % glucose solution intraoperatively for pleural coating (GPC) around an absorbable sheet to prevent postoperative SP recurrence. METHODS We evaluated 340 patients who underwent VATS between February 2011 and June 2017(88 patients:GPC group, 252:non-GPC group), and we retrospectively analyzed the efficacy of GPC in preventing postoperative SP recurrence. RESULTS One year postoperative recurrence rates of GPC and non-GPC groups were 9.0 and 17.9%,respectively. The log-rank test revealed GPC as a significant factor in preventing postoperative recurrence (p=0.020). No severe adverse events occurred in either group. Minor postoperative complications, viz., high blood sugar, high volume of chest tube drainage occurred in the GPC group. CONCLUSION Application of GPC is beneficial in reducing postoperative recurrence of SP.
Collapse
Affiliation(s)
- Kenji Tsuboshima
- Department of Thoracic and General Surgery, Takasago Municipal Hospital, Takasago, Japan
| | | | | | | | | | | | | |
Collapse
|
5
|
Tsuboshima K, Nagata M, Wakahara T, Matoba Y, Yamamoto M, Yamana H, Abe K, Oue H, Watanabe Y, Ono T. [Propensity-score-matched Comparison of Postoperative Pain Between Young and Elderly Patients Who Underwent Video-assisted Thoracoscopic Surgery for Spontaneous Pneumothorax]. Kyobu Geka 2016; 69:739-743. [PMID: 27476561] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
Video-assisted thoracoscopic surgery (VATS) is the standard treatment for spontaneous pneumothorax(SP). Although VATS has decreased the postoperative pain in comparison with conventional thoracotomy, the procedure still often requires sufficient postoperative pain management especially for young patients, and the present study on the postoperative pain management focused on the age difference was designed. Using the numerical rating scale, we compared postoperative pain between the young group(36 patients) and the elderly group (36 patients) selected by propensity score matching in order to adjust for the patients' backgrounds. Although the young group had significantly stronger pain than the elderly group immediately after surgery(4.9±2.5 vs.3.2±2.4, p=0.002), it improved promptly. Moreover, the young group required significantly more frequent continuous infusions of opioids after surgery( p=0.001). In conclusion, it is considered that the postoperative pain management in the pneumothorax surgery should be customized according to the age.
Collapse
Affiliation(s)
- Kenji Tsuboshima
- Department of Thoracic Surgery, Takasago Municipal Hospital, Takasago, Japan
| | | | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Kowatari M, Kubota T, Shibahara Y, Fujii T, Fukutani S, Takamiya K, Mizuno S, Yamana H. Application of a CZT detector to in situ environmental radioactivity measurement in the Fukushima area. Radiat Prot Dosimetry 2015; 167:348-352. [PMID: 25953790 DOI: 10.1093/rpd/ncv277] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
Instead of conventional Ge semiconductor detectors and NaI(Tl) scintillation spectrometers, an application of a CdZnTe semiconductor (CZT) whose crystal has the dimension of 1 cm cubic to the in situ environmental radioactivity measurement was attempted in deeply affected areas in Fukushima region. Results of deposition density on soil for (134)Cs/(137)Cs obtained seemed consistent, comparing obtained results with those measured by the Japanese government.
Collapse
Affiliation(s)
- M Kowatari
- Department of Radiation Protection, Nuclear Science Research Institute, Japan Atomic Energy Agency, Shirakata Shirane 2-4, Tokai-mura, Naka-gun, Ibaraki 319-1195, Japan
| | - T Kubota
- Research Reactor Institute, Kyoto University, Kumatori, Osaka 590-0494, Japan
| | - Y Shibahara
- Research Reactor Institute, Kyoto University, Kumatori, Osaka 590-0494, Japan
| | - T Fujii
- Research Reactor Institute, Kyoto University, Kumatori, Osaka 590-0494, Japan
| | - S Fukutani
- Research Reactor Institute, Kyoto University, Kumatori, Osaka 590-0494, Japan
| | - K Takamiya
- Research Reactor Institute, Kyoto University, Kumatori, Osaka 590-0494, Japan
| | - S Mizuno
- Nuclear Power Safety Division, Fukushima Prefectural Government, Fukushima 960-8670, Japan
| | - H Yamana
- Research Reactor Institute, Kyoto University, Kumatori, Osaka 590-0494, Japan
| |
Collapse
|
7
|
Maeda S, Ueda K, Yamana H, Tashiro-Yamaji J, Ibata M, Mikura A, Okada M, Yasuda E, Shibayama Y, Yoshino M, Kubota T, Yoshida R. Blood supply--susceptible formation of melanin pigment in hair bulb melanocytes of mice. Plast Reconstr Surg Glob Open 2015; 3:e328. [PMID: 25878939 PMCID: PMC4387150 DOI: 10.1097/gox.0000000000000284] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2014] [Accepted: 01/07/2015] [Indexed: 12/12/2022]
Abstract
BACKGROUND Allogeneic skin grafts onto C57BL/6 mice are rejected, and the rejected skin is replaced by surrounding skin with black hair. In contrast, syngeneic skin grafts are tolerated, and gray hair grows on the grafts. METHODS To explore the mechanism of gray hair growing on the tolerated skin grafts, we prepared full-thickness skin (2-cm square) autografts, 2 (2 cm + 2 cm) horizontal or vertical parallel incisions, and U-shaped (2 cm × 2 cm × 2 cm) flaps with or without pedicle vessels. The grafts, incisions, and flaps were fixed by suturing with string and protected by a transparent bandage. On day 14 after the operation, the bandages were removed to observe the color of the hair growing on the skin. RESULTS Skin autografts from wild-type or hepatocyte growth factor-transgenic (Tg) C57BL/6 mice survived with gray hair, whereas those from steel factor (Kitl)-Tg C57BL/6 mice survived with black hair. In addition, U-shaped flaps lacking both of the 2 main feeding vessels of wild-type mice had gray hair at the tip of the flaps. Light microscopy after staining with hematoxylin and eosin or dihydroxyphenylalanine showed that the formation of melanin pigment in the follicles, but not in the interadnexal skin, was susceptible to the blood supply. CONCLUSIONS Melanin pigment formation in the hair bulb melanocytes appeared to be susceptible to the blood supply, and melanocytosis was promoted in the follicles and in the epidermis of Kitl-Tg C57BL/6 mice.
Collapse
Affiliation(s)
- Shogo Maeda
- From the Department of Physiology, Osaka Medical College, Takatsuki, Japan; Department of Plastic and Reconstructive Surgery, Osaka Medical College, Takatsuki, Japan; Department of Pathology, Osaka Medical College, Takatsuki, Japan; and Division of Immunology, Department of Molecular and Cellular Biology, School of Life Science, Faculty of Medicine, Tottori University, Yonago, Japan
| | - Koichi Ueda
- From the Department of Physiology, Osaka Medical College, Takatsuki, Japan; Department of Plastic and Reconstructive Surgery, Osaka Medical College, Takatsuki, Japan; Department of Pathology, Osaka Medical College, Takatsuki, Japan; and Division of Immunology, Department of Molecular and Cellular Biology, School of Life Science, Faculty of Medicine, Tottori University, Yonago, Japan
| | - Hidenori Yamana
- From the Department of Physiology, Osaka Medical College, Takatsuki, Japan; Department of Plastic and Reconstructive Surgery, Osaka Medical College, Takatsuki, Japan; Department of Pathology, Osaka Medical College, Takatsuki, Japan; and Division of Immunology, Department of Molecular and Cellular Biology, School of Life Science, Faculty of Medicine, Tottori University, Yonago, Japan
| | - Junko Tashiro-Yamaji
- From the Department of Physiology, Osaka Medical College, Takatsuki, Japan; Department of Plastic and Reconstructive Surgery, Osaka Medical College, Takatsuki, Japan; Department of Pathology, Osaka Medical College, Takatsuki, Japan; and Division of Immunology, Department of Molecular and Cellular Biology, School of Life Science, Faculty of Medicine, Tottori University, Yonago, Japan
| | - Minenori Ibata
- From the Department of Physiology, Osaka Medical College, Takatsuki, Japan; Department of Plastic and Reconstructive Surgery, Osaka Medical College, Takatsuki, Japan; Department of Pathology, Osaka Medical College, Takatsuki, Japan; and Division of Immunology, Department of Molecular and Cellular Biology, School of Life Science, Faculty of Medicine, Tottori University, Yonago, Japan
| | - Ayako Mikura
- From the Department of Physiology, Osaka Medical College, Takatsuki, Japan; Department of Plastic and Reconstructive Surgery, Osaka Medical College, Takatsuki, Japan; Department of Pathology, Osaka Medical College, Takatsuki, Japan; and Division of Immunology, Department of Molecular and Cellular Biology, School of Life Science, Faculty of Medicine, Tottori University, Yonago, Japan
| | - Masashi Okada
- From the Department of Physiology, Osaka Medical College, Takatsuki, Japan; Department of Plastic and Reconstructive Surgery, Osaka Medical College, Takatsuki, Japan; Department of Pathology, Osaka Medical College, Takatsuki, Japan; and Division of Immunology, Department of Molecular and Cellular Biology, School of Life Science, Faculty of Medicine, Tottori University, Yonago, Japan
| | - Emi Yasuda
- From the Department of Physiology, Osaka Medical College, Takatsuki, Japan; Department of Plastic and Reconstructive Surgery, Osaka Medical College, Takatsuki, Japan; Department of Pathology, Osaka Medical College, Takatsuki, Japan; and Division of Immunology, Department of Molecular and Cellular Biology, School of Life Science, Faculty of Medicine, Tottori University, Yonago, Japan
| | - Yuro Shibayama
- From the Department of Physiology, Osaka Medical College, Takatsuki, Japan; Department of Plastic and Reconstructive Surgery, Osaka Medical College, Takatsuki, Japan; Department of Pathology, Osaka Medical College, Takatsuki, Japan; and Division of Immunology, Department of Molecular and Cellular Biology, School of Life Science, Faculty of Medicine, Tottori University, Yonago, Japan
| | - Miya Yoshino
- From the Department of Physiology, Osaka Medical College, Takatsuki, Japan; Department of Plastic and Reconstructive Surgery, Osaka Medical College, Takatsuki, Japan; Department of Pathology, Osaka Medical College, Takatsuki, Japan; and Division of Immunology, Department of Molecular and Cellular Biology, School of Life Science, Faculty of Medicine, Tottori University, Yonago, Japan
| | - Takahiro Kubota
- From the Department of Physiology, Osaka Medical College, Takatsuki, Japan; Department of Plastic and Reconstructive Surgery, Osaka Medical College, Takatsuki, Japan; Department of Pathology, Osaka Medical College, Takatsuki, Japan; and Division of Immunology, Department of Molecular and Cellular Biology, School of Life Science, Faculty of Medicine, Tottori University, Yonago, Japan
| | - Ryotaro Yoshida
- From the Department of Physiology, Osaka Medical College, Takatsuki, Japan; Department of Plastic and Reconstructive Surgery, Osaka Medical College, Takatsuki, Japan; Department of Pathology, Osaka Medical College, Takatsuki, Japan; and Division of Immunology, Department of Molecular and Cellular Biology, School of Life Science, Faculty of Medicine, Tottori University, Yonago, Japan
| |
Collapse
|
8
|
Yamana H, Matsui H, Fushimi K, Yasunaga H. Treatment options and outcomes of hospitalised tuberculosis patients: a nationwide study. Int J Tuberc Lung Dis 2014; 19:120-6. [PMID: 25519801 DOI: 10.5588/ijtld.14.0333] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Abstract
SETTING Although standardised multidrug treatments exist, mortality among hospitalised tuberculosis (TB) patients is high. OBJECTIVE To characterise TB patients requiring acute hospital care and identify factors associated with in-hospital mortality. DESIGN Using a Japanese national database of acute-care hospitals, we identified patients with sputum smear-positive pulmonary TB who were discharged (both deceased and alive) between July 2010 and March 2013. Demographic characteristics, comorbidity, procedures and treatments were examined. We performed a multivariable logistic regression analysis to identify risk factors for in-hospital mortality. RESULTS Of 877 treated patients (566 males, mean age 74.5 years) identified, 152 (17.3%) died. A standard four-drug regimen of isoniazid (INH), rifampicin (RMP), ethambutol (EMB) and pyrazinamide was given to 279 (31.8%) patients, and INH, RMP and EMB to 335 (38.2%) patients. Multivariable analysis showed that the three-drug regimen was significantly associated with higher rates of in-hospital mortality (OR 1.87, 95%CI 1.07-3.27, P = 0.028). Other factors associated with in-hospital death were age, male sex, smoking habit, emergency admission, dementia and severe respiratory condition. CONCLUSION The risk factors for in-hospital death identified include the use of the three-drug regimen. Treatment choice could influence the outcome of hospitalised TB patients.
Collapse
Affiliation(s)
- H Yamana
- Department of Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo, Tokyo, Japan; Bunkyo City Public Health Center, Tokyo, Japan
| | - H Matsui
- Department of Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo, Tokyo, Japan
| | - K Fushimi
- Department of Health Policy and Informatics, Tokyo Medical and Dental University Graduate School of Medicine, Tokyo, Japan
| | - H Yasunaga
- Department of Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo, Tokyo, Japan
| |
Collapse
|
9
|
Yamana H, Tashiro-Yamaji J, Hayashi M, Maeda S, Shimizu T, Tanigawa N, Uchiyama K, Kubota T, Yoshida R. Down-regulated expression of monocyte/macrophage major histocompatibility complex receptors in human and mouse monocytes by expression of their ligands. Clin Exp Immunol 2014; 178:118-28. [PMID: 24842626 DOI: 10.1111/cei.12383] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 05/12/2014] [Indexed: 11/27/2022] Open
Abstract
Mouse monocyte/macrophage major histocompatibility complex (MHC) receptor 1 (MMR1; or MMR2) specific for H-2D(d) (or H-2K(d) ) molecules is expressed on monocytes from non-H-2D(d) (or non-H-2K(d) ), but not those from H-2D(d) (or H-2K(d) ), inbred mice. The MMR1 and/or MMR2 is essential for the rejection of H-2D(d) - and/or H-2K(d) -transgenic mouse skin onto C57BL/6 (H-2D(b) K(b) ) mice. Recently, we found that human leucocyte antigen (HLA)-B44 was the sole ligand of human MMR1 using microbeads that had been conjugated with 80 types of HLA class I molecules covering 94·2% (or 99·4%) and 92·4% (or 96·2%) of HLA-A and B molecules of Native Americans (or Japanese), respectively. In the present study, we also explored the ligand specificity of human MMR2 using microbeads. Microbeads coated with HLA-A32, HLA-B13 or HLA-B62 antigens bound specifically to human embryonic kidney (HEK)293T or EL-4 cells expressing human MMR2 and to the solubilized MMR2-green fluorescent protein (GFP) fusion protein; and MMR2(+) monocytes from a volunteer bound HLA-B62 molecules with a Kd of 8·7 × 10(-9) M, implying a three times down-regulation of MMR2 expression by the ligand expression. H-2K(d) (or H-2D(d) ) transgene into C57BL/6 mice down-regulated not only MMR2 (or MMR1) but also MMR1 (or MMR2) expression, leading to further down-regulation of MMR expression. In fact, monocytes from two (i.e. MMR1(+) /MMR2(+) and MMR1(-) /MMR2(-) ) volunteers bound seven to nine types of microbeads among 80, indicating ≤ 10 types of MMR expression on monocytes. The physiological role of constitutive MMRs on monocytes possibly towards allogeneic (e.g. fetal) cells in the blood appears to be distinct from that of inducible MMRs on macrophages toward allografts in tissue.
Collapse
Affiliation(s)
- H Yamana
- Department of Physiology, Osaka Medical College, Takatsuki, Japan; Department of General and Gastroenterological Surgery, Osaka Medical College, Takatsuki, Japan
| | | | | | | | | | | | | | | | | |
Collapse
|
10
|
|
11
|
Shima I, Sasaguri Y, Kakegawa T, Fujita H, Yamana H, Irie K, Morimatsu M. Treatment for superficial esophageal cancer based on histological features and gross appearance. Int J Oncol 2012; 5:315-20. [PMID: 21559591 DOI: 10.3892/ijo.5.2.315] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
According to the depth of invasion, sixty-one superficial esophageal cancers (SECs) were subclassified as follows: intraepithelial cancer (ep), mucosal cancer invading to the lamina propria mucosa (lpm), or to the muscularis mucosa (mm), and submucosal cancer limited to the inner one-third of the submucosal layer (sm1), to the middle one-third (sm2), or invading into the outer one-third (sm3) to investigate the relationship between the depth of invasion and gross type classified according to the Guidelines of the Japanese Research Society for Esophageal Disease. Our results show that the SECs comprised of 9 ep cancers, 8 lpm, 6 mm, 6 sm1, 19 sm2 and 13 sm3, none of the ep or lpm cancers had either lymph node metastasis or recurrence and one-third of the mm and sml cancers had metastasis only in the mediastinal nodes. One-third of the sm2 and sm3 cancers, otherwise, revealed nodal involvement at surgery, and one-fourth of those recurred postoperatively. Recurrence in the cervical nodes was found in 9% of these cancers. All the SECs of the gross types including protruding type, slightly elevated type more than 2 cm in diameter and distinctly depressed type were submucosal cancers, whereas all the SECs showing the gross types including flat type and slightly elevated type less than 2 cm in diameter were ep or lpm cancers. Therefore, we concluded that for SEC evaluated as flat or slightly elevated type less than 2 cm in diameter by the endoscopic examination, less radical treatment such as endoscopic mucosal resection (EMR) should be performed at first.
Collapse
Affiliation(s)
- I Shima
- UNIV OCCUPAT & ENVIRONM HLTH,DEPT PATHOL,YAHATANISHI KU,KITAKYUSHU 870,JAPAN. KURUME UNIV,DEPT PATHOL,KURUME,FUKUOKA 830,JAPAN. KURUME UNIV,DEPT SURG,KURUME,FUKUOKA 830,JAPAN. UNIV OCCUPAT & ENVIRONM HLTH,DEPT PATHOL & CELL BIOL,KITAKYUSHU 870,JAPAN
| | | | | | | | | | | | | |
Collapse
|
12
|
Shima I, Sasaguri Y, Arima N, Yamana H, Fujita H, Morimatsu M, Nagase H. Expression of epidermal growth-factor (EGF), matrix metalloproteinase-9 (mmp-9) and proliferating cell nuclear antigen (pcna) in esophageal cancer. Int J Oncol 2012; 6:833-9. [PMID: 21556608 DOI: 10.3892/ijo.6.4.833] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
Abstract
Expression of human epidermal growth factor (EGF) and matrix metalloproteinase-9 (MMP-9/gelatinase B) was examined immunohistochemically in 62 cases of surgically resected esophageal carcinomas, and the correlation between EGF expression and the proliferative activity of the tumors was studied by analysing the number of proliferating cell nuclear antigen (PCNA)-positive cells. Expression of EGF and MMP-9 was observed in 16 (38.1%) and 18 (42.9%) of the 42 superficial carcinomas and 8 (40%) and 14 (70%) of the 20 advanced carcinomas, respectively. The differences in the MMP-9 expression between the superficial carcinomas and the advanced carcinomas was significant (p<0.05). The synchronous expression of EGF and MMP-9 was observed in 15 (24.2%) of 62 carcinomas, i.e. 62.5% of the 24 EGF-positive tumors expressed MMP-9, but there was no statistically significant correlation between the expression of EGF and MMP-9. The relationships between EGF expression and tumor proliferative activity and prognostic factors were investigated. The PCNA grades were significantly higher in tumors with EGF-positive than those with EGF-negative expression (p<0.05) and the EGF expression showed a good correlation between the expression of MMP-9 and vascular invasion (p<0.01). The expression of MMP-9 was stronger in the advanced than the superficial carcinomas and there was a good correlation with vascular invasion (p<0.01). In a follow-up study of 55 patients, those with tumor that expressed MMP-9 or had a high PCNA grade showed a poor prognosis. Taken together, these observations suggest that both EGF and MMP-9 participate in the invasive phenotype in human esophageal carcinoma, but the expression of EGF is not directly related to the expression of MMP-9. Additional growth factors and cytokines may be involved in regulation of MMP-9 expression in this carcinoma.
Collapse
Affiliation(s)
- I Shima
- UNIV OCCUPAT & ENVIRONM HLTH,SCH MED,DEPT PATHOL,YAHATA KU,KITAKYUSHU,FUKUOKA 807,JAPAN. KURUME UNIV,SCH MED,DEPT SURG,KURUME,FUKUOKA 830,JAPAN. KURUME UNIV,SCH MED,DEPT PATHOL,KURUME,FUKUOKA 830,JAPAN. UNIV KANSAS,MED CTR,DEPT BIOCHEM & MOLEC BIOL,KANSAS CITY,KS 66160
| | | | | | | | | | | | | |
Collapse
|
13
|
Tashiro-Yamaji J, Shimizu T, Hayashi M, Yamana H, Tanigawa N, Uchiyama K, Kubota T, Yoshida R. Specific binding of HLA-B44 to human macrophage MHC receptor 1 on monocytes. Gene 2012; 501:127-34. [DOI: 10.1016/j.gene.2012.04.020] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2012] [Accepted: 04/09/2012] [Indexed: 11/25/2022]
|
14
|
Inoue Y, Hayashi M, Komeda K, Masubuchi S, Yamamoto M, Yamana H, Kayano H, Shimizu T, Asakuma M, Hirokawa F, Miyamoto Y, Takeshita A, Shibayama Y, Uchiyama K. Resection margin with anatomic or nonanatomic hepatectomy for liver metastasis from colorectal cancer. J Gastrointest Surg 2012; 16:1171-80. [PMID: 22370732 DOI: 10.1007/s11605-012-1840-7] [Citation(s) in RCA: 44] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/14/2011] [Accepted: 02/07/2012] [Indexed: 01/31/2023]
Abstract
BACKGROUND When hepatectomy is used as a primary treatment for liver metastasis from colorectal cancer (CRCLM), the balance between surgical curability and functional preservation of the remnant liver is of great importance. METHODS A total of 108 patients who underwent initial hepatectomy for CRCLM were retrospectively analyzed with respect to tumor extent, operative method, and prognosis, including recurrence. RESULTS The 1-, 2-, 3-, and 5-year overall survival rates (OS) for all patients were 90.5%, 77.8%, 63.2%, and 51.6%, respectively. Multivariate analysis indicated serum carbohydrate antigen 19-9 (CA 19-9) level after hepatectomy (<36 or ≥36 mAU/mL) and presence of recurrence as independent prognostic factors of OS (P = 0.0458 and 0.0249, respectively), and tumor depth of colorectal cancer (<se (a2) vs. ≥se (a2)) and serum CA 19-9 level after hepatectomy as the significant factors affecting disease-free survival (DFS) (P = 0.0025 and 0.00138, respectively). Neither resection margin nor type of hepatectomy (anatomic or nonanatomic) for CRCLM was a significant prognostic factor for OS or DFS or CRCLM recurrence, including intrahepatic recurrence. CONCLUSIONS In CRCLM, we believe that nonanatomic hepatectomy with narrow margin is indicated, and optimal treatment would include functional preservation of as much of the remnant liver as possible.
Collapse
Affiliation(s)
- Yoshihiro Inoue
- Department of General and Gastroenterological Surgery, Osaka Medical College Hospital, 2-7 Daigaku-machi, Takatsuki, Osaka, 569-8686, Japan.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Seki N, Takenaka M, Toh U, Kawahara A, Fujii T, Yamaguchi R, Yamana H, Yano H, Shirouzu K, Kage M. 284 Expression of Cancer-testis Antigens in Breast Cancer. Eur J Cancer 2012. [DOI: 10.1016/s0959-8049(12)70351-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
16
|
Hirao M, Ando N, Tsujinaka T, Udagawa H, Yano M, Yamana H, Nagai K, Mizusawa J, Nakamura K. Influence of preoperative chemotherapy for advanced thoracic oesophageal squamous cell carcinoma on perioperative complications. Br J Surg 2011; 98:1735-41. [PMID: 21918956 DOI: 10.1002/bjs.7683] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 07/01/2011] [Indexed: 01/12/2023]
Abstract
BACKGROUND The Japan Clinical Oncology Group (JCOG) 9907 trial has changed the standard of care for advanced thoracic oesophageal cancer in Japan from postoperative chemotherapy to preoperative chemotherapy. The impact of preoperative chemotherapy on the risk of developing postoperative complications remains controversial. This article reports the safety analysis of JCOG9907, focusing on risk factors for postoperative complications. METHODS Patients with potentially resectable advanced thoracic oesophageal squamous cell carcinoma were randomized to either postoperative or preoperative chemotherapy followed by transthoracic oesophagectomy with D2-3 lymphadenectomy. Chemotherapy consisted of two cycles of cisplatin and 5-fluorouracil. Clinical baseline data, intraoperative complications, postoperative complications and in-hospital mortality, collected on the case report forms in a predetermined format, were analysed. Univariable and multivariable analyses were used to explore the risk of postoperative complications in relation to treatment group, age, sex, tumour depth, nodal metastasis, stage and location. RESULTS Of 330 patients randomized, 166 were assigned to receive postoperative chemotherapy and 164 preoperative chemotherapy; 162 and 154 patients respectively underwent surgery. The incidence of intraoperative complications, postoperative complications and in-hospital mortality was similarly low in both groups. Multivariable analysis showed that age, sex and tumour location were independently associated with an increase in postoperative complications, but preoperative chemotherapy was not. CONCLUSION Preoperative chemotherapy does not increase the risk of complications or hospital mortality after surgery for advanced thoracic oesophageal cancer.
Collapse
Affiliation(s)
- M Hirao
- Department of Surgery, National Hospital Organization, Osaka National Hospital, Osaka, Japan.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Tanaka T, Fujita H, Matono S, Nagano T, Shirouzu K, Yamana H. 6552 POSTER Long-term Outcomes and Prognostic Factors of Extended Esophagectomy for Submucosal Esophageal Cancer. Eur J Cancer 2011. [DOI: 10.1016/s0959-8049(11)71863-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
18
|
Inoue Y, Tashiro-Yamaji J, Hayashi M, Kiyonari H, Shimizu T, Ibata M, Yamana H, Kubota T, Tanigawa N, Yoshida R. Transgene number-dependent, gene expression rate-independent rejection of Dd-, Kd-, or DdKd-transgened mouse skin or tumor cells from C57BL/6 (DbKb) mice. Microbiol Immunol 2011; 55:446-53. [DOI: 10.1111/j.1348-0421.2011.00337.x] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
19
|
Inoue Y, Hayashi M, Satou N, Miyamoto Y, Hirokawa F, Asakuma M, Shimizu T, Kayano H, Yamamoto M, Yamana H, Okuda J, Egashira Y, Tanigawa N. Prognostic Clinicopathological Factors After Curative Resection of Small Bowel Adenocarcinoma. J Gastrointest Cancer 2011; 43:272-8. [PMID: 21607548 DOI: 10.1007/s12029-011-9290-0] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
Affiliation(s)
- Yoshihiro Inoue
- Department of General and Gastroenterological Surgery, Osaka Medical College Hospital, 2-7 Daigaku-machi, Takatsuki City, Osaka, 569-8686, Japan.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Sasatomi T, Ogata Y, Shirouzu K, Yamana H. Monitoring of the CD3+CD8+/CD4+CD25+FoxP3+ ratio in PBMC in colorectal chemotherapy patients. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e14160] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
21
|
Tanaka T, Fujita H, Matono S, Nagano T, Nishimura K, Murata K, Shirouzu K, Suzuki G, Hayabuchi N, Yamana H. Outcomes of multimodality therapy for stage IVB esophageal cancer with distant organ metastasis (M1-Org). Dis Esophagus 2010; 23:646-51. [PMID: 20545979 DOI: 10.1111/j.1442-2050.2010.01069.x] [Citation(s) in RCA: 40] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
Esophageal cancer patients with distant organ metastasis have usually been treated only to palliate symptoms without multimodality therapy. The current study evaluates the role of multimodality therapy in esophageal squamous cell cancer patients with distant organ metastasis. Between February 1988 and January 2007, 80 esophageal squamous cell cancer patients with distant organ metastases were treated at our institution. Multimodality therapy was performed in 58 patients: 43 patients received chemoradiotherapy, 13 underwent surgery followed by chemotherapy and/or radiation therapy, and two received chemotherapy or chemoradiotherapy followed by surgery. Thirteen patients received single-modality therapy; chemotherapy, radiotherapy, or surgery alone. The remaining nine patients received best supportive care alone. The metastatic organ was the liver (n= 40), the lungs (n= 33), bone (n= 10), and other (n= 6). Nine patients had metastasis in two organs. There was no difference in the median survival among the sites of organ metastasis, lung, liver, or bone (P= 0.8786). The survival of patients treated with multimodality therapy was significantly better than that of the patients who received single-modality therapy or best supportive care alone (P < 0.0001). In patients treated with multimodallity therapy, there was no difference in survival for patients treated with surgery compared with patients treated without surgery (P= 0.1291). This retrospective study involves an inevitable issue of patient selection bias. However, these results suggested that multimodality therapy could improve survival of the esophageal squamous cell cancer patients with distant organ metastasis.
Collapse
Affiliation(s)
- T Tanaka
- Department of Surgery, Kurume University School of Medicine, Kurume University Hospital, Kurume-shi, Fukuoka, Japan.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Abstract
Esophageal small cell carcinoma (SmCC) has been regarded as a rare and aggressive tumor with early metastasis. The optimal treatment has not yet been established, and the role of surgery has remained controversial. In this retrospective study, we report seven cases studies of SmCC of the esophagus and analyze the clinical outcomes after surgery. Between 1986 and 2007, there were seven patients with esophageal SmCC treated surgically in our institution. All the patients with clinically limited disease underwent transthoracic esophagectomy with lymphadenectomy. Lymph node involvement was found in all cases irrespective of the depth of tumor invasion. Three of the seven patients were diagnosed as having an extensive disease on pathological examination after esophagectomy. Five patients received postoperative chemotherapy. Two patients are alive with no recurrence at 16 months and at 45 months after surgery. Another one without chemotherapy survived 93 months and died of another disease. The remaining four patients died of recurrent disease or another disease. The median overall survival to date of these patients was 16 months (range 12-93 months). Esophagectomy with lymphadenectomy resulted in a relatively better survival in some patients with esophageal SmCC. We concluded that surgery may be helpful as part of multimodality treatment in selected patients with esophageal SmCC.
Collapse
Affiliation(s)
- T Tanaka
- Department of Surgery, Kurume University School of Medicine, Fukuoka, Japan.
| | | | | | | | | | | | | | | |
Collapse
|
23
|
Toh U, Otsuka H, Iwakuma N, Shirouzu K, Ogo E, Yamana H, Itoh K, Tanaka M, Fujii T. A phase II study of personalized selection of peptide vaccines combined with conventional chemo- or endocrine therapy for refractory breast cancer. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.tps173] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
24
|
Toh U, Yamana H, Koufuji K, Mine T, Aoyagi K, Miyagi M, Imaizumi T, Shirouzu K. Phase II study of S-1 in combination with paclitaxel as a first-line treatment for patients with advanced/recurrent gastric cancer. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.e15615] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e15615 Background: Taxanes and S-1 have been shown to be effective in patients with advanced gastric cancer and they have a considerable single-agent activity, respectively. We evaluated the combination of paclitaxel and S-1 as first-line chemotherapy for advanced or recurrent gastric cancer (AGC). Methods: All patients with histologically confirmed AGC with unresectable or metastatic diseases, measurable lesions, PS 0–2, age between 18 and 75, and no contraindication to chemotherapy were eligible in this study. Prior adjuvant chemotherapy finished at least 6 months before enrollment was allowed. Treatment included S-1 80 mg/m2 p.o. twice daily on days 1–14 and paclitaxel 60 mg/m2 i.v. on day 1, 8, 15 with a 2-week interval until disease progression or unacceptable toxicities. Results: Between MAY 2004 and Match 2008, total 20 pts were enrolled in this study. The median age was 56.5 years (range, 38–73). Nine pts had recurrent disease after previous curative gastrectomy and 8 had previous adjuvant chemotherapy. After a median 4 (range, 1–9) cycles of chemotherapy, 12 pts were evaluable for toxicity and 20 pts for response. In intention-to-treat analysis, the overall response rate was 62.9% (95% C.I., 36.2–69.6%), including 0 CR, 6 PRs, 8 SDs, and 6 PDs. After a median follow-up of 8.6 months (range, 0.9–17.9), median time to progression was 6.3 months (95% C.I., 3.6–6.9) and median overall survival was 11.6 months (95% C.I., 8.5–20.7). Commonly observed grade 3/4 adverse events were neutropenia (40% of patients), anemia (10%). There was no neutropenic fever or treatment-related death. Conclusions: The combination of paclitaxel and S-1 appear to have well efficacy, manageable toxicity and is well tolerated in patients with AGC. Further studies of this combination should be considered. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- U. Toh
- Kurume University School of Medicine, Kurume, Japan
| | - H. Yamana
- Kurume University School of Medicine, Kurume, Japan
| | - K. Koufuji
- Kurume University School of Medicine, Kurume, Japan
| | - T. Mine
- Kurume University School of Medicine, Kurume, Japan
| | - K. Aoyagi
- Kurume University School of Medicine, Kurume, Japan
| | - M. Miyagi
- Kurume University School of Medicine, Kurume, Japan
| | - T. Imaizumi
- Kurume University School of Medicine, Kurume, Japan
| | - K. Shirouzu
- Kurume University School of Medicine, Kurume, Japan
| |
Collapse
|
25
|
Takamiya K, Okumura R, Abe N, Nakano Y, Miyata K, Fukutani S, Taniguchi A, Yamana H. Development of a new control system for pneumatic transportation facility in KUR. J Radioanal Nucl Chem 2008. [DOI: 10.1007/s10967-008-1511-z] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
26
|
Toh U, Fujii T, Seki N, Nakagawa S, Mishima M, Fukunaga M, Ogo E, Yahara T, Yamana H, Shirouzu K. Strategy to augment the efficacy of immunotherapy for refractory breast cancer using trastuzumab combined adoptive cell therapy. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.3062] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
27
|
Toh U, Fujii T, Takamori S, Fukunaga M, Ogo E, Seki N, Yamana H, Shirouzu K. Combination of gemcitabine and adoptive cell therapy of autologous anti-tumor CTL induces clinical activities in patients with refractory lung cancer. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.3053] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
3053 Background: Cytotoxic T cells selectively kill autologous tumor cells is powerful for adoptive cell therapy of cancer. Gemcitabine (GEM) is able to induce molecular changes in cancer cells that make them to induce an antigen specific CTL response. This study was to evaluate the anti-tumor and the immunological activity using the CTL in combination with GEM. Methods: The 50Gy irradiated autologous tumor cells were cocultured with PBMCs and CTLs was developed with RPMI 1640 and rIL-2 (50 u/ml) for 7–14 days. Nine pts with non small cell lung cancer failed their prior chemotherapy were enrolled this pilot study. GEM regimen [intravenous (iv.) GEM (1000mg/m2) - day 1, 8 and 15 ] was started without CTL administration for 1st cycle. GEM was administered at least 2 cycles with a 1-week interval and combined with iv. CTL therapy (0.9 x 108 - 4.6 x 108 cells/injection + IL-2 0.4 MIU; biweekly for 6 to 12 injections) from 2nd cycle. The mean total administered T cells were reached to 3.9 x 109 - 5.6 x 109. PBMCs were analyzed their surface markers by Flow Cytometry and the cytokine productions of IFN-γ etc. in the serum were measured by ELISA before and after 1st cycle of GEM administration and 3rd cycles of CTL injection. Results: After finishing 2 cycles of GEM and 3 injections of CTL, the ratio of CD4/CD8 in PBMCs increased in 7/9 pts. In contrast, CD3/CD19 decreased in 6/9 pts. The cytokine production of IFN-γ in the serum revealed an increase after treatment, the levels of TGF-β were decreased simultaneously. There was no remarkable change in the levels of NKG2D in the PBMCs and MIG, IP10 in the serum. The clinical response showed PR/SD/PD was 2/5/2. The tumor marker proteins (CEA) were also decreased significantly in 4 of 9 pts. The adverse effects were tolerable with grade <2 fever, nausea and fatigue and no bone marrow suppression was observed. Conclusions: These results suggested the synergistic enhancement of antitumor effect might be induced between CTLs and anti-cancer agent GEM. Marked clinical responses were observed in two pts after the treatment. Thus this chemo-immunotherapy will be applicable for the patients with refractory lung cancer. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- U. Toh
- Kurume University School of Medicine, Kurume, Japan
| | - T. Fujii
- Kurume University School of Medicine, Kurume, Japan
| | - S. Takamori
- Kurume University School of Medicine, Kurume, Japan
| | - M. Fukunaga
- Kurume University School of Medicine, Kurume, Japan
| | - E. Ogo
- Kurume University School of Medicine, Kurume, Japan
| | - N. Seki
- Kurume University School of Medicine, Kurume, Japan
| | - H. Yamana
- Kurume University School of Medicine, Kurume, Japan
| | - K. Shirouzu
- Kurume University School of Medicine, Kurume, Japan
| |
Collapse
|
28
|
Toh U, Fujii T, Seki N, Ogo E, Shirouzu K, Yamana H. Intrapericardial cellular immunotherapy for malignant pericardial effusion using autologous IL-2-activated TILs. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.2555] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
2555 Background: Pericardial effusion (PE) and cardiac tamponade caused by malignant pericarditis are critical conditions in cancer patients, which still lack a recommended protocol for their long-term management. The aims of this study were to investigate the presence of cytotoxic T lymphocytes (CTLs) in malignant PE and to determine the clinical response to administering autologous tumor-infiltrating lymphocytes (TILs) into the pericardial cavity. Methods: Initially, we identified human lymphocyte antigen class-I-restricted and tumor-specific CTLs within the interleukin-2 (IL-2)-activated TILs in PEs from four patients, on the basis of interferon-g production and lactate dehydrogenase-release assays. Clinically we observed favorable responses to the pericardial transfer of IL-2-activated autologous TILs in four patients: one male with advanced esophageal cancer, one female with recurrent lung cancer and two female with recurrent breast cancer, respectively. Autologous TILs from PEs were expanded in vitro with IL-2, characterized for CD3, CD4 and CD8 markers, checked for contamination and then infused into the patient’s pericardial space through a catheter. This was repeated biweekly. Results: After treatment, there were no signs of recurrence of PE in either case, as determined by radiography, echocardiography and computed tomography. The only adverse effects seen were grade 1 fevers. Conclusions: These results suggested that intrapericardial cellular immunotherapy with autologous TILs could be a safe and effective treatment for controlling malignant pericarditis with associated cardiac tamponade, and that tumor-specific CTLs present in malignant PE might be important for tumor rejection. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- U. Toh
- Kurume University School of Medicine, Kurume, Fukouka, Japan; Kurume University School of Medicine, Kurume, Japan
| | - T. Fujii
- Kurume University School of Medicine, Kurume, Fukouka, Japan; Kurume University School of Medicine, Kurume, Japan
| | - N. Seki
- Kurume University School of Medicine, Kurume, Fukouka, Japan; Kurume University School of Medicine, Kurume, Japan
| | - E. Ogo
- Kurume University School of Medicine, Kurume, Fukouka, Japan; Kurume University School of Medicine, Kurume, Japan
| | - K. Shirouzu
- Kurume University School of Medicine, Kurume, Fukouka, Japan; Kurume University School of Medicine, Kurume, Japan
| | - H. Yamana
- Kurume University School of Medicine, Kurume, Fukouka, Japan; Kurume University School of Medicine, Kurume, Japan
| |
Collapse
|
29
|
Tayama K, Fujii T, Toh U, Yokoyama G, Miwa K, Takamori S, Shirouzu K, Ogo E, Yamana H. The synergistic clinical effect of autologous tumor-stimulated T lymphocyte and herceptin on the immunotherapy of breast cancer. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.775] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- K. Tayama
- Kurume Univ Sch of Medicine, Kurume, Japan
| | - T. Fujii
- Kurume Univ Sch of Medicine, Kurume, Japan
| | - U. Toh
- Kurume Univ Sch of Medicine, Kurume, Japan
| | | | - K. Miwa
- Kurume Univ Sch of Medicine, Kurume, Japan
| | | | | | - E. Ogo
- Kurume Univ Sch of Medicine, Kurume, Japan
| | - H. Yamana
- Kurume Univ Sch of Medicine, Kurume, Japan
| |
Collapse
|
30
|
Toh U, Yamana H, Fujii T, Tayama K, Miwa K, Horiuchi H, Kokanemaru M, Shirouzu K. The cell transfer immunotherapy of intra-arterial infusion for the patients with liver metastases of gastrointestinal and pancreas cancer. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.2581] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- U. Toh
- Kurume Univ Sch of Medicine, Kurume, Fukouka, Japan
| | - H. Yamana
- Kurume Univ Sch of Medicine, Kurume, Fukouka, Japan
| | - T. Fujii
- Kurume Univ Sch of Medicine, Kurume, Fukouka, Japan
| | - K. Tayama
- Kurume Univ Sch of Medicine, Kurume, Fukouka, Japan
| | - K. Miwa
- Kurume Univ Sch of Medicine, Kurume, Fukouka, Japan
| | - H. Horiuchi
- Kurume Univ Sch of Medicine, Kurume, Fukouka, Japan
| | | | - K. Shirouzu
- Kurume Univ Sch of Medicine, Kurume, Fukouka, Japan
| |
Collapse
|
31
|
Fujii T, Obata K, Kubota T, Kamiya M, Yamana H. Volatility of tellurium and various fission products in heated nitric acid solutions. J Radioanal Nucl Chem 2005. [DOI: 10.1007/s10967-005-0474-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
32
|
Toh U, Yamana H, Fujii T, Sasatomi T, Takamori S, Araki Y, Ogo E, Shirozou K. Repeated immune cell transfer therapy combined with non myeloablative chemotherapy in patients with refractory recurrent gastrointestinal and lung cancer. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.14_suppl.2541] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- U. Toh
- Kurume University School of Medicine, Kurume, Fukouka, Japan
| | - H. Yamana
- Kurume University School of Medicine, Kurume, Fukouka, Japan
| | - T. Fujii
- Kurume University School of Medicine, Kurume, Fukouka, Japan
| | - T. Sasatomi
- Kurume University School of Medicine, Kurume, Fukouka, Japan
| | - S. Takamori
- Kurume University School of Medicine, Kurume, Fukouka, Japan
| | - Y. Araki
- Kurume University School of Medicine, Kurume, Fukouka, Japan
| | - E. Ogo
- Kurume University School of Medicine, Kurume, Fukouka, Japan
| | - K. Shirozou
- Kurume University School of Medicine, Kurume, Fukouka, Japan
| |
Collapse
|
33
|
Sato Y, Maeda Y, Shomura H, Sasatomi T, Takahashi M, Une Y, Kondo M, Shinohara T, Hida N, Katagiri K, Sato K, Sato M, Yamada A, Yamana H, Harada M, Itoh K, Todo S. A phase I trial of cytotoxic T-lymphocyte precursor-oriented peptide vaccines for colorectal carcinoma patients. Br J Cancer 2004; 90:1334-42. [PMID: 15054451 PMCID: PMC2409683 DOI: 10.1038/sj.bjc.6601711] [Citation(s) in RCA: 36] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
Abstract
In most protocols of peptide-based vaccination, no consideration has been paid to whether or not peptide-specific cytotoxic T-lymphocyte (CTL) precursors are pre-existent in cancer patients. Initiation of immune boosting through vaccination is better than that of immune priming to induce prompt and strong immunity. In this study, 10 human histocompatibility leukocyte antigen-A24+ patients with advanced colorectal carcinomas were treated with up to four peptides that had been positive for pre-vaccination measurement of peptide-specific CTL precursors in the circulation (CTL precursor-oriented peptide vaccine). No severe adverse effect was observed, although local pain and fever of grade I or II were observed. Post-vaccination peripheral blood mononuclear cells (PBMCs) from five patients demonstrated an increased peptide-specific immune response to the peptides. Increased CTL response to cancer cells was detected in post-vaccination PBMCs of five patients. Antipeptide immunoglobulin G became detectable in post-vaccination sera of seven patients. Three patients developed a positive delayed-type hypersensitivity response to at least one of the peptides administrated. One patient was found to have a partial response; another had a stable disease, sustained through 6 months. These results encourage further development of CTL precursor-oriented vaccine for colorectal cancer patients.
Collapse
Affiliation(s)
- Y Sato
- First Department of Surgery, Hokkaido University School of Medicine, Sapporo, Japan.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Koga T, Fujii T, Yanaga H, Ogo E, Yokoyama G, Mishima M, Yamana H, Shirouzu K. Induction of apoptosis in mouse mammary epithelial cells RIII/MG by epigallocatechin gallate (EGCG). EJC Suppl 2004. [DOI: 10.1016/s1359-6349(04)91051-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022] Open
|
35
|
Abstract
A 73-year-old woman complaining of sudden hoarseness visited our hospital 17 days after the onset. The upper gastrointestinal contrast study showed a shallow ulcer crater with moderate bulging in the upper thoracic esophagus. Endoscope and computed tomography revealed an esophageal foreign body, a Press Through Pack (PTP), in the esophageal ulcer. The PTP could be removed endoscopically. Two months after extraction of the PTP, the patient was taking normal food orally and was discharged. The esophageal perforation, looking like a diverticle, was still present more than 1 year after the onset.
Collapse
Affiliation(s)
- T Sudo
- Department of Surgery, Kurume University School of Medicine, Kurume-city, Fukuoka, Japan
| | | | | | | | | |
Collapse
|
36
|
Matono S, Tanaka T, Sueyoshi S, Sasahara H, Yamana H, Fujita H, Shirouzu K. 970 Increased gap junctional intercellular communication in esophageal cancer augments the bystander effect in HSV-tk/GCV suicide gene therapy. EJC Suppl 2003. [DOI: 10.1016/s1359-6349(03)90997-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
37
|
Maeda Y, Hida N, Niiya F, Katagiri K, Harada M, Yamana H, Kamura T, Takahashi M, Sato Y, Todo S, Itoh K. Detection of peptide-specific CTL-precursors in peripheral blood lymphocytes of cancer patients. Br J Cancer 2002; 87:796-804. [PMID: 12232766 PMCID: PMC2364263 DOI: 10.1038/sj.bjc.6600548] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2002] [Revised: 07/03/2002] [Accepted: 07/22/2002] [Indexed: 11/09/2022] Open
Abstract
Development of therapeutic vaccines is one of the major areas of tumour immunotherapy today. However, clinical trials of peptide-based cancer vaccines have rarely resulted in tumour regression. This failure might be due to an insufficient induction of cytotoxic T lymphocytes in the current regimes, in which cytotoxic T lymphocytes-precursors in pre-vaccination peripheral blood mononuclear cells are not measured. Initiation of immune-boosting through vaccination could be better than that of immune-priming with regard to induction of prompt and strong immunity. If this is also the case for therapeutic vaccines, pre-vaccination measurement of peptide-specific cytotoxic T lymphocytes-precursors will be important. In the present study, we investigated whether cytotoxic T lymphocytes-precursors reacting to 28 kinds of peptides of vaccine candidates (13 and 15 peptides for HLA-A24(+) and HLA-A2(+) patients, respectively) were detectable in pre-vaccination peripheral blood mononuclear cells of 80 cancer patients. Peptide-specific cytotoxic T lymphocytes-precursors were found to be detectable in peripheral blood mononuclear cells of the majority of cancer patients (57 out of 80 cases, 71%). The mean numbers of positive peptides were 2.0 peptides per positive case. Peripheral blood mononuclear cells incubated with positive peptides, not with negative peptides, showed significant levels of HLA-class-I-restricted cytotoxicity to cancer cells. The profiles of positive peptides entirely varied among patients, and were not influenced by the cancer origin. These results may provide a scientific basis for the development of a new approach to cancer immunotherapy, e.g.) cytotoxic T lymphocytes-precursor-oriented peptide vaccine.
Collapse
Affiliation(s)
- Y Maeda
- Department of Immunology, Kurume University, 67 Asahi-machi, Kurume, 830-0011, Japan
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Nakamura S, Katoh T, Furutaka K, Wada H, Harada H, Baba T, Fujii T, Yamana H. Measurement of Thermal Neutron Capture Cross Section and Resonance Integral of 90Sr and 166mHo. J NUCL SCI TECHNOL 2002. [DOI: 10.1080/00223131.2002.10875088] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
39
|
|
40
|
Miyagi Y, Imai N, Sasatomi T, Yamada A, Mine T, Katagiri K, Nakagawa M, Muto A, Okouchi S, Isomoto H, Shirouzu K, Yamana H, Itoh K. Induction of cellular immune responses to tumor cells and peptides in colorectal cancer patients by vaccination with SART3 peptides. Clin Cancer Res 2001; 7:3950-62. [PMID: 11751487] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/23/2023]
Abstract
The tumor-rejection antigen SART3 possesses two antigenic epitopes (SART3(109-118) and SART3(315-323)) capable of inducing HLA-A24-restricted and tumor-specific CTLs. To determine its safety and ability to generate antitumor immune responses, 12 patients with advanced colorectal cancer were administered s.c. vaccinations of these peptides. No severe adverse events were associated with the vaccinations. Significant levels of increased cellular immune responses to both HLA-A24+ colon cancer cells and the vaccinated peptide were observed in the postvaccination peripheral blood mononuclear cells in 7 of 11 and 7 of 10 patients tested, respectively, and the higher responses were observed in those patients vaccinated with the highest dose (3 mg/injection) of the peptides. These results encourage further development of SART3 peptide vaccine for colorectal cancer patients.
Collapse
Affiliation(s)
- Y Miyagi
- Department of Surgery, Kurume University School of Medicine, 67 Asahi Machi, Kurume 830-0011, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Fujii T, Tanaka Y, Tanaka T, Matono S, Sueyoshi S, Fujita H, Shirouzu K, Kato S, Yamana H. [Experimental gene therapy using p21/WAF1 gene in esophageal squamous cell carcinoma--adenovirus infection and gene gun technology]. Gan To Kagaku Ryoho 2001; 28:1651-4. [PMID: 11708000] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/22/2023]
Abstract
p21/WAF1 (p21) inhibits the activity of the cyclin/cdk complex and controls the G1 to S cell phase transition. In the present study, we used a recombinant adenoviral approach and gene gun technology to introduce p21 into esophageal cancer cells in order to assess the effect of p21 on cell growth. Infection with the p21 adenovirus (AdV) using gene gun technology resulted in inhibition of TE9 and KE3 cell growth. The levels of involucrin, which is a marker of squamous epithelium differentiation, markedly increased at 48 h and 72 h after p21 AdV infection in TE9 cells. These results indicate that p21 plays an important role in esophageal cancer cell proliferation. Overexpression of the p21 gene can inhibit cell growth and induce differentiation in esophageal cancer cells. p21 gene therapy may prove beneficial in the treatment of esophageal cancer.
Collapse
Affiliation(s)
- T Fujii
- Dept. of Surgery, Kurume University School of Medicine, Kurume University Research Center for Innovative Cancer Therapy
| | | | | | | | | | | | | | | | | |
Collapse
|
42
|
Sasatomi T, Toh U, Miyagi Y, Ishibashi N, Araki Y, Ogata Y, Yamana H, Shirouzu K. [Cellular immunotherapy for local recurrence of rectal cancer after surgery by activated lymphocyte administration--a case report]. Gan To Kagaku Ryoho 2001; 28:1692-5. [PMID: 11708011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/22/2023]
Abstract
UNLABELLED Intrapelvic recurrence of the rectal cancer after surgery is a challenging status. We report here a case of intrapelvic tumor due to the recurrence of rectal cancer postoperatively treated by adoptive cellular immunotherapy. CASE REPORT A 57-year-old Japanese man with an intrapelvic tumor showing bone destruction due to the recurrence of rectal cancer after abdomino-peritoneal resection was diagnosed by CT scan. He consented to simultaneous adaptive cellular immunotherapy for local recurrent lesions by administration of the activated lymphocytes. The tumor sample used for the activation of PBMC was obtained by operation. Tumor cells were prepared by mincing and enzymatic digestion of the tumor sample, and they were irradiated with a dosage of 50 Gy. Peripheral blood samples were collected from the same patient. PBMC for about 2 weeks to prepare cells for treatment were obtained from the blood sample. One million PBMC were incubated in 2 ml of the culture medium containing 10(5) irradiated autologous tumor cells and 100 IU/ml recombinant IL-2. The activated PBMCs, as autologous cancer specific killer T cells, were administered by direct regional injection (from 2 million to 8 x 10(7) cells). These injections were given repeatedly about once a week at 2-week intervals for three months. The surface phenotypes of activated PBMC or PBMC were tested by two color immunostaining technique with anti-CD3, -CD4, -CD8 and also anti-CD16, -CD25 or -CD56. Natural killer cell activity was also investigated. The clinical outcome was evaluated by CT scan and serum CEA levels. In the cultured activated PBMCs, NK cell activity was 40%, both CD3 and CD4 positive cells was 30%, and both CD3 and CD8 positive cells was 48%. There were far more CD8 cells than CD4 cells. In the PBMC, NK cell activity had increased, both CD3 and CD4 positive cells had decreased and both CD3 and CD8 positive cells had increased. There were then predominantly more CD8 cells than CD4 cells by repeated administration of the cultured activated PBMCs. The only adverse effect was grade 2 fever. Serum CEA levels fell from 293.7 ng/ml to 160 ng/ml, but the tumor size on the CT scan was slightly increased except for the directly administered region. We have been observing him as an outpatient.
Collapse
Affiliation(s)
- T Sasatomi
- Dept. of Surgery, Kurume University School of Medicine
| | | | | | | | | | | | | | | |
Collapse
|
43
|
Kihara C, Tsunoda T, Tanaka T, Yamana H, Furukawa Y, Ono K, Kitahara O, Zembutsu H, Yanagawa R, Hirata K, Takagi T, Nakamura Y. Prediction of sensitivity of esophageal tumors to adjuvant chemotherapy by cDNA microarray analysis of gene-expression profiles. Cancer Res 2001; 61:6474-9. [PMID: 11522643] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/21/2023]
Abstract
We applied cDNA microarray analyses of 9216 genes to establish a genetic method for predicting the outcome of adjuvant chemotherapy to esophageal cancers. We analyzed expression profiles of 20 esophageal cancer tissues from patients who were treated with the same adjuvant chemotherapy after removal of tumor by operation, and we attempted to find genes associated with the duration of survival after surgery. By comparing expression profiles of those cancer tissues, we identified by statistical analysis 52 genes that were likely to be correlated with prognosis and possibly with sensitivity/resistance to the anticancer drugs. We also developed a drug response score based on the differential expression of these genes, and we found a significant correlation between the drug response score and individual patients' prognoses. Our results indicated that this scoring system, based on microarray analysis of selected genes, is likely to have great potential for predicting the prognosis of individual cancer patients with the adjuvant chemotherapy.
Collapse
Affiliation(s)
- C Kihara
- Human Genome Center, Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
44
|
Hayashi K, Ando N, Watanabe H, Ide H, Nagai K, Aoyama N, Takiyama W, Ishida K, Isono K, Makuuchi H, Imamura M, Shinoda M, Ikeuchi S, Kabuto T, Yamana H, Fukuda H. Phase II evaluation of protracted infusion of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG) Trial (JCOG9407). Jpn J Clin Oncol 2001; 31:419-23. [PMID: 11689594 DOI: 10.1093/jjco/hye090] [Citation(s) in RCA: 115] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND Surgery for advanced esophageal carcinoma has its limits as regards aggressiveness and therapeutic effect, therefore effective multimodality treatment is required to obtain better survival. The objective of this study was to evaluate whether daily continuous infusion of CDDP could achieve a higher clinical response rate with less toxicity than its drip infusion in the previous phase II study that we had conducted. METHODS Patients with primary extensive or relapsed esophageal carcinoma after esophagectomy, which had distant organ metastasis and histologically proven SCC, were eligible for this study. A dose of 20 mg/m(2) of cisplatin and 800 mg/m(2) of 5-fluorouracil was given by continuous infusion for 24 h on days 1-5. This treatment was repeated every 4 weeks for up to four cycles. A total of 36 men and six women with a median age of 64 (range 39-75) years were registered and 36 patients were eligible. RESULTS The overall response rate of the registered patients was 33.3% (12/36) and the median response duration was 175 days. Median survival time was 201.5 days and the 1-year survival rate was 27.8%. Change from bolus to continuous infusion of cisplatin affected neither the type nor the degree of toxicity. CONCLUSION Daily continuous infusion of cisplatin was not associated with higher response or lower toxicity than those seen with the high-dose bolus or multibolus treatment regimens. We conclude that this regimen in this setting is not worthy of further phase III trials. JEOG is now evaluating other drug combination regimens.
Collapse
Affiliation(s)
- K Hayashi
- Department of Surgery, Institute of Gastroenterology,Tokyo Women's Medical University, Tokyo, Japan.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Nagamatsu Y, Shima I, Yamana H, Fujita H, Shirouzu K, Ishitake T. Preoperative evaluation of cardiopulmonary reserve with the use of expired gas analysis during exercise testing in patients with squamous cell carcinoma of the thoracic esophagus. J Thorac Cardiovasc Surg 2001; 121:1064-8. [PMID: 11385372 DOI: 10.1067/mtc.2001.113596] [Citation(s) in RCA: 97] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
OBJECTIVE We evaluated the usefulness of analyzing expired gas during exercise testing for the prediction of postoperative cardiopulmonary complications in patients with esophageal carcinoma. BACKGROUND DATA Radical esophagectomy with 3-field lymphadenectomy is performed in patients with thoracic esophageal carcinoma but has a high risk of postoperative complications. To reduce the surgical risk, we performed preoperative risk analysis using 8 factors. Although hospital mortality was decreased when this risk analysis was used, severe cardiopulmonary complications still occurred. METHODS The study group consisted of 91 patients who had undergone curative esophagectomy with 3-field lymphadenectomy. The maximum oxygen uptake, anaerobic threshold, vital capacity, percent vital capacity, forced expiratory volume in 1 second, percent forced expiratory volume, V.(25)/HT, forced expired flow at 75% of forced vital capacity to height ratio (FEF(75%)/HT), forced expired flow at 50% to 75% of forced vital capacity ratio (FEF(50%)/FEF(75%)), percent diffusion capacity for carbon monoxide, and arterial oxygen tension were measured. Patients were divided into 2 groups on the basis of the presence or absence of postoperative cardiopulmonary complications. RESULTS Only the maximum oxygen uptake was significantly different between the 2 groups. All patients were grouped according to the value of the maximum oxygen uptake, and the occurrence of postoperative cardiopulmonary complications was calculated for each group. A cardiopulmonary complication rate of 86% was found for patients with a maximum oxygen uptake of less than 699 mL. min(-1). m(-2); for those with a value of 700 to 799 mL. min(-1). m(-2), the complication rate was 44%. CONCLUSIONS The maximum oxygen uptake obtained by expired gas analysis during exercise testing correlates with the postoperative cardiopulmonary complication rate. On the basis of these results, esophagectomy with 3-field lymphadenectomy can be safely performed in patients with a maximum oxygen uptake of at least 800 mL. min(-1). m(-2).
Collapse
Affiliation(s)
- Y Nagamatsu
- Department of Surgery, Saiseikai Yahata General Hospital, 5-9-27 Harunomachi Yahatahigashi-ku Kitakyushu City, 805-8527, Japan
| | | | | | | | | | | |
Collapse
|
46
|
Tanaka T, Matono S, Yamana H, Sueyoshi S, Toh U, Fujita H, Shirouzu K. PPARgamma expression in esophageal cancer and effect of PPARgamma ligands. Eur J Cancer 2001. [DOI: 10.1016/s0959-8049(01)80954-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
47
|
Niiya F, Mine T, Toh U, Yamana H, Itoh K. [Cancer vaccine with peptides derived from tumor rejection antigens]. Nihon Rinsho 2001; 59 Suppl 4:438-42. [PMID: 11424421] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/20/2023]
Affiliation(s)
- F Niiya
- Department of Surgery, Kurume University School of Medicine
| | | | | | | | | |
Collapse
|
48
|
Matono S, Tanaka T, Yamana H, Sueyoshi S, Toh U, Fujita H, Shirouzu K. Bystander effect is dependent on gap junction in esophageal cancer. Eur J Cancer 2001. [DOI: 10.1016/s0959-8049(01)81552-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
49
|
Fujita H, Sueyoshi S, Yamana H, Shinozaki K, Toh U, Tanaka Y, Mine T, Kubota M, Shirouzu K, Toyonaga A, Harada H, Ban S, Watanabe M, Toda Y, Tabuchi E, Hayabuchi N, Inutsuka H. Optimum treatment strategy for superficial esophageal cancer: endoscopic mucosal resection versus radical esophagectomy. World J Surg 2001; 25:424-31. [PMID: 11344392 DOI: 10.1007/s002680020053] [Citation(s) in RCA: 123] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
This study was designed to determine the optimum treatment for a superficial esophageal cancer involving the mucosal or submucosal layer of the esophagus. The subjects were 150 patients with a superficial esophageal cancer who underwent endoscopic mucosal resection (EMR) or esophagectomy in Kurume University Hospital from 1981 to 1997. The mortality and morbidity rates, survival rate, and recurrence rate were retrospectively compared for (1) 35 patients who underwent EMR and 37 patients who underwent esophagectomy for a mucosal esophageal cancer and (2) 45 patients who underwent extended radical esophagectomy and 33 patients who underwent less radical esophagectomy for a submucosal esophageal cancer. Among the 72 patients with a mucosal cancer, lymph node metastasis/recurrence was observed in only one (1%); whereas of 78 patients with a submucosal cancer it was observed in 30 (38%). Among patients with a mucosal cancer the mortality and morbidity rates after EMR were lower than for those after esophagectomy. The survival rate after EMR was the same as that after esophagectomy. No recurrence was observed after either treatment modality. Among the patients with a submucosal cancer, the survival rate was higher and the recurrence rate lower after extended radical esophagectomy; than after less radical esophagectomy; the mortality and morbidity rates after extended radical esophagectomy were the same as those after less radical esophagectomy. Multivariate analysis demonstrated that the treatment modality (EMR versus esophagectomy) did not influence the survival of patients with a mucosal esophageal cancer, whereas it strongly influenced the survival of patients with a submucosal esophageal cancer. We concluded that EMR was the mainstay of treatment for a mucosal esophageal cancer, and extended radical esophagectomy was the mainstay of treatment for a submucosal esophageal cancer.
Collapse
Affiliation(s)
- H Fujita
- Department of Surgery, Kurume University School of Medicine, 67 Asahi-machi, Kurume City, Fukuoka 830-0011, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Harashima N, Tanaka K, Sasatomi T, Shimizu K, Miyagi Y, Yamada A, Tamura M, Yamana H, Itoh K, Shichijo S. Recognition of the Lck tyrosine kinase as a tumor antigen by cytotoxic T lymphocytes of cancer patients with distant metastases. Eur J Immunol 2001; 31:323-32. [PMID: 11180095 DOI: 10.1002/1521-4141(200102)31:2<323::aid-immu323>3.0.co;2-0] [Citation(s) in RCA: 59] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
The Lck protein (p56(lck)), a src family tyrosine kinase that is essential for T cell development and function, is aberrantly expressed in metastatic colon cancers. p56(lck) seems to facilitate the malignant transformation of epithelial cells through initiation of anchorage-independent proliferation. We demonstrate that the lck gene encodes antigenic epitopes recognized by the HLA class I-restricted and tumor-specific CTL of metastatic cancer patients. Lck peptides augmented CTL activity in peripheral blood mononuclear cells (PBMC) of colon and other epithelial cancer patients with distant metastases, but not those without distant metastases. CTL precursors recognizing the Lck peptide were identified in freshly prepared PBMC of patients with distant metastases, and their frequency was significantly augmented by stimulation with the peptide. Thus, Lck peptides could be useful in developing a specific immunotherapy for cancer patients with distant metastases.
Collapse
Affiliation(s)
- N Harashima
- Department of Immunology, Kurume University School of Medicine, Kurume, Japan
| | | | | | | | | | | | | | | | | | | |
Collapse
|